Device Trial Radar · NCT00121472
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
194
Actual
Start
Mar 2005
Primary completion
Nov 2006
Study completion May 2010
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- Collaborators
- Thoratec Corporation
- First posted
- Jul 21, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as a bridge to cardiac transplantation in end-stage heart failure patients who are listed for cardiac transplant but are at imminent risk of dying. The HeartMate II LVAS was approved by the US FDA on April 21, 2008, as a bridge to cardiac transplantation (reference PMA P060040). It was approved for commercial distribution in Canada on May 20, 2009 (reference Medical Device Licence #79765). Patients enrolled into the clinical trial will continue to be followed until all have reached a clinical outcome.
Conditions
- Heart Failure, Congestive
- Ventricular Dysfunction
- Cardiomyopathies
Interventions
Thoratec HeartMate II Left Ventricular Assist System (LVAS)Device
Implantation of ventricular assist device to provide hemodynamic support
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: 180 days
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Sharp Memorial Hospital
San Diego, California
33 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.